USPTO Examiner SILVERMAN JANICE Y - Art Unit 1616

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
184297572-(BENZO[D]OXAZOL-2-YL)-N'- (ISONICOTINOYLOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDFebruary 2024August 2024Allow710YesNo
184297522-(BENZO[D]OXAZOL-2-YL)-N'- (ISONICOTINOYLOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDFebruary 2024August 2024Allow610YesNo
18419071Termite Trailing and Recruitment Product and ProcessJanuary 2024September 2024Allow820YesNo
183827312-(BENZO[D]OXAZOL-2-YL)-N'- (ISONICOTINOYLOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDOctober 2023October 2024Allow1221YesNo
18367829Termite Trailing and Recruitment Product and ProcessSeptember 2023June 2024Abandon910NoNo
18089652STABLE READY-TO-USE CARMUSTINE PHARMACEUTICAL COMPOSITIONDecember 2022November 2023Allow1011YesNo
17871189PROCESSES FOR IMMOBILISING BIOLOGICAL ENTITIESJuly 2022February 2024Allow1911YesNo
17869665TOPICAL COMPOSITIONSJuly 2022March 2024Allow1921NoNo
17725320COMPOSITIONS FOR THE TREATMENT OF HYPERKERATOSIS DISORDERSApril 2022September 2024Abandon2911YesNo
17695166HETEROCYCLIC-DITHIOL CLICK CHEMISTRYMarch 2022September 2024Allow3021NoNo
17685038TREPROSTINIL DERIVATIVES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONSMarch 2022July 2024Allow2921YesNo
17577564PYRROLIDINONES AS HERBICIDESJanuary 2022July 2022Allow610YesNo
17531731Plug Product and a Method of Using the Plug Product for Tooth-Associated PainNovember 2021October 2024Abandon3501NoNo
17519377PLANT HEALTH EFFECT OF PURPUREOCILLIUM LILACINUMNovember 2021October 2024Abandon3521YesNo
17507413COMPOSITION FOR SKIN WHITENING COMPRISING CARVEDILOLOctober 2021August 2024Abandon3421YesNo
17490885MICRONUTRIENT COMPOSITIONS AND SYSTEMS AND METHODS OF USING SAMESeptember 2021April 2024Abandon3111NoNo
17468717NATURAL LUBRICANT COMPOSITION AND A TABLETSeptember 2021September 2023Allow2511YesNo
17468293METHOD FOR INHIBITING CORONAVIRUS AND METHOD FOR TREATING DISEASE ASSOCIATED WITH CORONAVIRUS INFECTIONSeptember 2021October 2024Abandon3721NoNo
17403679Lip Balm Containing Caffeine, Nicotine or TestosteroneAugust 2021April 2024Allow3211YesNo
17378485MULTILAYER WATER DISPERSIBLE FILM HAVING IMPROVED GERMINATION OF SEEDS AND SOIL FERTILITYJuly 2021December 2024Abandon4121YesNo
17373714NOVEL GLUE FOR EMBOLIZATION OF LYMPHATIC LEAKAGEJuly 2021February 2024Abandon3111NoNo
17421710PHARMACEUTICAL COMPOSITION COMPRISING SPHERICAL AGGLOMERATES OF TIMAPIPRANTJuly 2021June 2024Abandon3620NoNo
17421701PROCESS FOR PREPARING SPHERICAL AGGLOMERATES OF TIMAPIPRANTJuly 2021June 2024Abandon3620YesNo
17297349COSMETIC COMPOSITIONS AND METHODS OF USEMay 2021November 2024Abandon4221NoNo
17317829OXYGEN-GENERATING BIODEGRADABLE SURGICAL MESHMay 2021October 2024Abandon4221NoNo
17315382Neutralizing Agent with Disinfectant and Deodorizing EffectMay 2021February 2024Abandon3310NoNo
17290234COMPOSITIONS COMPRISING HALAUXIFEN AND OTHER HERBICIDES AND METHODS THEREOFApril 2021August 2024Abandon3910NoNo
17229265Method Of Treating InflammationApril 2021May 2024Abandon3711NoNo
17268022STABLE READY-TO-USE CARMUSTINE PHARMACEUTICAL COMPOSITIONFebruary 2021May 2023Abandon2721YesNo
17267656METHOD FOR TREATING PRIMARY SCLEROSING CHOLANGITISFebruary 2021October 2024Abandon4511NoNo
17157701COMPOSITIONS COMPRISING ORGANIC MINERAL CHELATES, NIACINAMIDE, AND HEMP OIL AND USES THEREOF FOR NEUROPROTECTION, CARDIOPROTECTION, DETOXIFICATION, IMMUNE SUPPORT, AND ANTI-AGINGJanuary 2021January 2024Abandon3611NoNo
17145716WAVELENGTH SPECTRUM ENHANCEMENT FOR PLANT PHOTOSYNTHESISJanuary 2021October 2023Abandon3311NoNo
17134800ENCAPSULATING AGENT WITH IMPROVED PROPERTIES ADAPTED FOR CELL ENCAPSULATIONDecember 2020March 2023Abandon2701NoNo
17129697Methods for Producing Fullerene that is Bioavailable via Inhalation or Other Absorption ModalityDecember 2020May 2023Allow2911YesNo
17126901MULTI-PARTICULATE PHARMACEUTICAL COMPOSITION, IMMEDIATE RELEASE PELLETS, SUSTAINED RELEASE PELLETS, ENTERIC RELEASE PELLETS AND USE THEREOFDecember 2020April 2023Abandon2820NoNo
17253206PESTICIDALLY ACTIVE AZETIDINE SULFONES AMIDE ISOXAZOLINE DERIVATIVESDecember 2020May 2024Abandon4101NoNo
17252349COMPOUNDS HAVING A NITROGEN-CONTAINING UNSATURATED SIX-MEMBERED RING AND AGRICULTURAL AND HORTICULTURAL FUNGICIDES CONTAINING THE SAME AS ACTIVE INGREDIENTSDecember 2020June 2024Allow4221YesNo
17118312SURFACTANTS FOR AGRICULTURAL PRODUCTSDecember 2020September 2023Allow3321YesNo
17056151THIOL-BASED MULTIVALENT DRUG DELIVERY COMPOSITIONSNovember 2020November 2024Abandon4821YesNo
17095997READY TO USE BIODEGRADABLE AND BIOCOMPATIBLE CELL-BASED NERVE CONDUIT FOR NERVE INJURY AND A METHOD OF PREPARATION THEREOFNovember 2020December 2023Allow3711YesNo
17053837NEAR-IR ACTIVATABLE FLUORESCENT SMALL MOLECULES WITH DUAL MODES OF CYTOTOXICITYNovember 2020January 2023Allow2620YesNo
17092257COMBINATION THERAPEUTICS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER DISEASESNovember 2020January 2023Abandon2611NoNo
17089497ELECTROSPRAYED AND ELECTROSPUN CANNABINOID COMPOSITIONS AND PROCESS TO PRODUCENovember 2020July 2023Abandon3211YesNo
17047027HETEROARYL-TRIAZOLE AND HETEROARYL-TETRAZOLE COMPOUNDS AS PESTICIDESOctober 2020June 2024Allow4411YesNo
17039859PROBIOTIC MICROCAPSULESeptember 2020November 2023Allow3821YesNo
17041919ESTERS OF HETEROCYCLIC COMPOUNDS HAVING A NEMATOCIDAL ACTIVITY, THEIR AGRONOMIC COMPOSITIONS AND THEIR USESeptember 2020February 2024Abandon4101NoNo
17029580HIP LABRUM SCAFFOLDSSeptember 2020November 2024Abandon5041YesNo
16981643BONEGRAFT SUBSTITUTE AND METHOD OF MANUFACTURESeptember 2020March 2024Allow4231YesNo
16999871REACTIVE MULTI-ARM POLYMERS HAVING BRANCHED END GROUPSAugust 2020August 2024Allow4831YesYes
16961147COMPOSITIONS AND METHODS FOR THE TREATMENT OF LUNG EMPHYSEMA AND OTHER FORMS OF COPDJuly 2020January 2024Abandon4240YesNo
16920460TOPICAL COMPOSITIONSJuly 2020October 2022Abandon2710NoNo
16901602ANTIBACTERIAL PHOTODYNAMIC THERAPY USING COPPER-CYSTEAMINE NANOPARTICLESJune 2020August 2024Allow5021YesYes
16767611PESTICIDAL COMPOSITIONS AND METHODSMay 2020July 2023Abandon3821NoNo
16767726MICROBIOCIDAL THIAZOLE DERIVATIVESMay 2020September 2023Allow3931YesNo
16767048HETEROCYCLIC COMPOUNDS AS PESTICIDESMay 2020November 2022Abandon2901NoNo
16877980SUPRAMOLECULAR BIOMEDICAL POLYMERSMay 2020September 2023Allow4031YesNo
16763939METHOD FOR MANUFACTURING A HYPERBRANCHED POLYESTER POLYOL DERIVATIVEMay 2020December 2024Abandon5540NoYes
16763737METHOD FOR INDUCING ACQUIRED RESISTANCE IN A PLANTMay 2020July 2024Allow5040YesNo
15930799USE OF HIF-2alpha INHIBITORS FOR TREATING CHONDROSARCOMA, OR PREVENTING RECURRENCE AND METASTASIS THEREOFMay 2020February 2023Allow3321YesNo
16762345S1PR2 ANTAGONISTS FOR TREATING DISEASES INVOLVING ABNORMAL IMMUNE RESPONSESMay 2020June 2022Abandon2501NoNo
16760784ANTIMICROBIAL FLOOR COATINGS AND FORMULATIONSApril 2020March 2024Abandon4640YesNo
16757119Macrophage Targeted ImmunotherapeuticsApril 2020November 2023Abandon4331YesNo
16756045HERBICIDAL FORMULATION IN THE FORM OF MICROEMULSIONApril 2020February 2024Abandon4641NoNo
16844151BIOLOGICAL FUNGICIDE COMPOSED BY PLANT EXTRACTSApril 2020September 2021Allow1820YesNo
16832264COATING FOR JOINT IMPLANTSMarch 2020March 2024Abandon4721NoNo
16650623COMPOSITIONS FOR WOUND TREATMENTMarch 2020May 2023Abandon3811NoNo
16649621Pyrazine-4-Carbamate or -Urea Derivatives As HerbicidesMarch 2020February 2023Allow3421NoNo
16820232FLEXIBLE HOLLOW STRUCTURE, ADHESIVE TAPE, AND FUNCTIONAL ADHESIVE SHEETMarch 2020January 2023Abandon3401NoNo
16815756MACRONUTRIENT COMPOUNDSMarch 2020October 2023Abandon4321NoNo
16644707ACETIC ACID-BASED HERBICIDE COMPOSITIONMarch 2020January 2024Abandon4632YesNo
16643345COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPASEFebruary 2020September 2023Abandon4221YesNo
16792400METHOD AND COMPOSITION FOR INHIBITING THE GROWTH OF PSEUDOMONAS SYRINGAE ON A PLANT MATERIAL, AND KIT FOR TREATING THE SAMEFebruary 2020October 2023Abandon4431NoNo
16639322HERBICIDAL COMPOSITIONFebruary 2020May 2023Abandon3921NoNo
16635039SYSTEMS AND METHODS FOR WOUND DEBRIDEMENTJanuary 2020May 2023Abandon3901NoNo
16751441AGRICULTURAL ADJUVANT COMPRISING MICROFIBRILLATED CELLULOSEJanuary 2020April 2024Allow5131YesNo
16750735MULTIFUNCTIONAL AGRICULTURAL ADJUVANT COMPOSITIONSJanuary 2020September 2023Allow4471YesNo
16631624SUBSTITUTED 3-HETEROARYLOXY-1H-PYRAZOLES AND SALTS THEREOF AND THEIR USE AS HERBICIDAL ACTIVE SUBSTANCESJanuary 2020August 2022Abandon3101NoNo
16631393COATED IMPLANTABLE DEVICEJanuary 2020April 2024Allow5141YesNo
16630330HETEROCYCLIC-DITHIOL CLICK CHEMISTRYJanuary 2020August 2022Abandon3111NoNo
16618121SPRAY COMPOSITIONS OF CHITOSAN FOR WOUND HEALINGNovember 2019August 2023Abandon4540NoNo
16617238COSMETICNovember 2019April 2023Allow4140NoNo
16695888DRUG DELIVERY SYSTEM FOR ULTRA-LOW DOSE ESTROGEN COMBINATIONS AND METHODS AND USES THEREOFNovember 2019February 2023Abandon3921NoNo
16484536PURIFIED POLLEN PARTICLES AND USE THEREOF FOR ADMINISTERING NANOSYSTEMSNovember 2019July 2024Abandon5931NoNo
16684157METHOD OF MAKING A FLAVONOID SOLUTION AND APPLICATIONS THEREOF FOR PLANT GROWTH PROMOTION, SEED COATING, PATHOGEN ELIMINATION, AND HERBICIDE STUNTING EFFECT REMOVALNovember 2019February 2024Allow5161YesNo
16613078PYRAZOLE-3-CARBOXYLIC ACID AMIDE DERIVATIVE AND PEST CONTROL AGENTNovember 2019March 2024Allow5241YesNo
16676077METHODS AND MATERIALS FOR IMMUNOMODULATION OF TISSUE GRAFTSNovember 2019January 2023Abandon3801NoNo
16665217HERBICIDAL COMPOSITIONS AND METHODS OF USE THEREOFOctober 2019September 2021Abandon2311NoNo
16600489AGRICULTURAL MICROBIAL COATINGOctober 2019October 2022Abandon3631YesNo
16604354AGED ROSE EXTRACT AND PREPARATION METHOD THEREOFOctober 2019May 2023Abandon4330NoNo
16499333EX-VIVO CULTURE SYSTEM AND METHODS OF USING SAMESeptember 2019January 2024Allow5141YesNo
16498897COMPOUNDS AND METHODS USEFUL FOR TREATING OR PREVENTING CANCERSSeptember 2019November 2022Allow3821YesNo
16498006ALLEVIATION OF CORN ROOTWORM DAMAGE WITH MICROBIAL SEED TREATMENTSSeptember 2019February 2022Abandon2820YesNo
16546400ANTIBACTERIAL COLLOID AND METHOD FOR MANUFACTURING THE SAMEAugust 2019November 2023Abandon5141NoNo
16485834HERBICIDAL MIXTURE FOR USE ON WEEDSAugust 2019September 2021Abandon2501NoNo
16538866Lip Balm Containing Caffeine, Nicotine or TestosteroneAugust 2019October 2021Abandon2730YesNo
16479586LYOPHILIZED PLACENTAL COMPOSITE SHEET AND USES THEREOFJuly 2019November 2020Abandon1611NoNo
16510466NANOFORMULATIONS OF NEUROPEPTIDES AND METHOD OF MAKING SAMEJuly 2019September 2021Abandon2630YesNo
16508406ENCAPSULATED SEEDJuly 2019August 2024Abandon6080YesNo
16455966Skin Care CompositionJune 2019April 2024Abandon5761YesNo
16457173ION INCORPORATED PLASMA SPRAYED HYDROXYAPATITE COATINGS AND METHOD OF MAKING THE SAMEJune 2019August 2024Abandon6061YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SILVERMAN, JANICE Y.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
3
Examiner Affirmed
0
(0.0%)
Examiner Reversed
3
(100.0%)
Reversal Percentile
91.1%
Higher than average

What This Means

With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
7
Allowed After Appeal Filing
3
(42.9%)
Not Allowed After Appeal Filing
4
(57.1%)
Filing Benefit Percentile
70.3%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 42.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner SILVERMAN, JANICE Y - Prosecution Strategy Guide

Executive Summary

Examiner SILVERMAN, JANICE Y works in Art Unit 1616 and has examined 139 patent applications in our dataset. With an allowance rate of 26.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.

Allowance Patterns

Examiner SILVERMAN, JANICE Y's allowance rate of 26.6% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by SILVERMAN, JANICE Y receive 2.64 office actions before reaching final disposition. This places the examiner in the 77% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SILVERMAN, JANICE Y is 41 months. This places the examiner in the 20% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +48.0% benefit to allowance rate for applications examined by SILVERMAN, JANICE Y. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 13.1% of applications are subsequently allowed. This success rate is in the 8% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 12.5% of cases where such amendments are filed. This entry rate is in the 12% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 57.1% of appeals filed. This is in the 29% percentile among all examiners. Of these withdrawals, 25.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 105.3% are granted (fully or in part). This grant rate is in the 94% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.